Hepatitis B virus (HBV) remains a major global health problem with 257 million chronically infected individuals worldwide, of whom approximately 20 million are co-infected with hepatitis delta virus (HDV). Progress toward a better understanding of the complex interplay between these two viruses and the development of novel therapies have been hampered by the scarcity of suitable cell culture models that mimic the natural environment of the liver. Here, we established HBV and HBV/HDV co-infections and super-infections in self-assembling co-cultured primary human hepatocytes (SACC-PHHs) for up to 28 days in a 384-well format and highlight the suitability of this platform for high-throughput drug testing. We performed RNA sequencing at days 8 and 28 on SACC-PHHs, either HBV mono-infected or HBV/HDV co-infected. Our transcriptomic analysis demonstrates that hepatocytes in SACC-PHHs maintain a mature hepatic phenotype over time, regardless of infection condition. We confirm that HBV is a stealth virus, as it does not induce a strong innate immune response; rather, oxidative phosphorylation and extracellular matrix-receptor interactions are dysregulated to create an environment that promotes persistence. Notably, HDV co-infection also did not lead to statistically significant transcriptional changes across multiple donors and replicates. The lack of innate immune activation is not due to SACC-PHHs being impaired in their ability to induce interferon stimulated genes (ISGs). Rather, polyinosinic:polycytidylic acid exposure activates ISGs, and this stimulation significantly inhibits HBV infection, yet only minimally affects the ability of HDV to infect and persist. Conclusion: These data demonstrate that the SACC-PHH system is a versatile platform for studying HBV/HDV co-infections and holds promise for performing chemical library screens and improving our understanding of the host response to such infections.
Hepatitis B virus (HBV) remains a major global health problem with 257 million chronically infected individuals worldwide, of whom approximately 20 million are co-infected with hepatitis delta virus (HDV). Progress toward a better understanding of the complex interplay between these two viruses and the development of novel therapies have been hampered by the scarcity of suitable cell culture models that mimic the natural environment of the liver. Here, we established HBV and HBV/HDV co-infections and super-infections in self-assembling co-cultured primary human hepatocytes (SACC-PHHs) for up to 28 days in a 384-well format and highlight the suitability of this platform for high-throughput drug testing. We performed RNA sequencing at days 8 and 28 on SACC-PHHs, either HBV mono-infected or HBV/HDV co-infected. Our transcriptomic analysis demonstrates that hepatocytes in SACC-PHHs maintain a mature hepatic phenotype over time, regardless of infection condition. We confirm that HBV is a stealth virus, as it does not induce a strong innate immune response; rather, oxidative phosphorylation and extracellular matrix-receptor interactions are dysregulated to create an environment that promotes persistence. Notably, HDV co-infection also did not lead to statistically significant transcriptional changes across multiple donors and replicates. The lack of innate immune activation is not due to SACC-PHHs being impaired in their ability to induce interferon stimulated genes (ISGs). Rather, polyinosinic:polycytidylic acid exposure activates ISGs, and this stimulation significantly inhibits HBV infection, yet only minimally affects the ability of HDV to infect and persist. Conclusion: These data demonstrate that the SACC-PHH system is a versatile platform for studying HBV/HDV co-infections and holds promise for performing chemical library screens and improving our understanding of the host response to such infections.
Authors: Benjamin Y Winer; Elham Shirvani-Dastgerdi; Yaron Bram; Julie Sellau; Benjamin E Low; Heath Johnson; Tiffany Huang; Gabriela Hrebikova; Brigitte Heller; Yael Sharon; Katja Giersch; Sherif Gerges; Kathleen Seneca; Mihai-Alexandru Pais; Angela S Frankel; Luis Chiriboga; John Cullen; Ronald G Nahass; Marc Lutgehetmann; Jared E Toettcher; Michael V Wiles; Robert E Schwartz; Alexander Ploss Journal: Sci Transl Med Date: 2018-06-27 Impact factor: 17.956
Authors: Antje Blank; Christoph Markert; Nicolas Hohmann; Alexandra Carls; Gerd Mikus; Thorsten Lehr; Alexander Alexandrov; Mathias Haag; Matthias Schwab; Stephan Urban; Walter E Haefeli Journal: J Hepatol Date: 2016-04-27 Impact factor: 25.083
Authors: Yi Ni; Florian A Lempp; Stefan Mehrle; Shirin Nkongolo; Christina Kaufman; Maria Fälth; Jan Stindt; Christian Königer; Michael Nassal; Ralf Kubitz; Holger Sültmann; Stephan Urban Journal: Gastroenterology Date: 2013-12-19 Impact factor: 22.682
Authors: Severin Gudima; Yiping He; Ning Chai; Volker Bruss; Stephan Urban; William Mason; John Taylor Journal: J Virol Date: 2008-05-21 Impact factor: 5.103
Authors: Chun Shen Lim; Vitina Sozzi; Margaret Littlejohn; Lilly K W Yuen; Nadia Warner; Brigid Betz-Stablein; Fabio Luciani; Peter A Revill; Chris M Brown Journal: Microb Genom Date: 2021-01
Authors: Shilpa Tiwari-Heckler; Eric U Yee; Yusuf Yalcin; Jiwoon Park; Duc-Huy T Nguyen; Wenda Gao; Eva Csizmadia; Nezam Afdhal; Kenneth J Mukamal; Simon C Robson; Michelle Lai; Robert E Schwartz; Z Gordon Jiang Journal: Cell Rep Date: 2021-10-26 Impact factor: 9.423
Authors: Lise Lauterbach-Rivière; Maïwenn Bergez; Saskia Mönch; Bingqian Qu; Maximilian Riess; Florian W R Vondran; Juliane Liese; Veit Hornung; Stephan Urban; Renate König Journal: Viruses Date: 2020-05-29 Impact factor: 5.048
Authors: Vincent Turon-Lagot; Antonio Saviano; Catherine Schuster; Thomas F Baumert; Eloi R Verrier Journal: J Clin Med Date: 2020-01-14 Impact factor: 4.241